Company intelligence / Profile preview

Native Pro

Unknown, Unknown, Unknownnativecustombaggers.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Native Pharmaceuticals positions itself as an innovator developing high-quality medicines with a focus on unmet medical needs. No specific clinical results are disclosed publicly[1].

Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

GrBmut-TRA

Pre-clinical

Indications: HER2-positive cancers

Beyond the preview

Go deeper on Native Pro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Native Pro.

Explore the full profile